The company, undergoing a corporate name change to Adia Med, Inc., has significantly shifted its business model toward advanced medical treatments and biologics. The company has secured Institutional Review Board approval for four clinical studies using AdiaVita stem cell and exosome therapies, including a flagship kidney health study for chronic kidney disease and an autism study in Winter Park that has completed enrollment.
Cyborg Score Rationale
The company shows strong operational momentum with 146% Q1 2026 revenue growth and expanding clinical programs, but trades on OTC markets with limited liquidity and historically minimal profitability. Clinical validation is underway, positioning potential long-term value creation, though near-term execution risk remains elevated for a micro-cap healthcare company.
Top Insights
Revenue in 2025 reached $700,508, representing a 10,879.75% increase compared to the prior year's $6,380, demonstrating acceleration from near-zero baseline
The company launched subsidiary ADIA Life LLC to centralize distribution of Adia Labs products and manage a nationwide distributor network (timing not specified in available sources)
In May 2026, the company announced IRB approval and ClinicalTrials.gov submission for a randomized, controlled study testing AdiaVita stem cell and exosome therapy in adults with chronic kidney disease
The company has an effective Form 10 registration and requested SIC code 2836 to align revenue classification with biologic products, signaling transition from supplement to therapeutics
Named Competitors
AthroStemm — Stem cell and regenerative medicine therapies
Stemedica — Cell therapy and regenerative medicine platform
RegenNow — Regenerative medicine clinic network
Recent Developments
(Q1 2026) 146% year-over-year revenue growth to $176,275 with 381% gross profit increase to $67,577
(May 2026) IRB approval for chronic kidney disease study registered on ClinicalTrials.gov with recruitment beginning; autism study actively treating patients
(April 2026) Announced corporate name change to Adia Med, Inc. to reflect shift to regenerative medicine and biologics focus
(February 2026) Announced ambitious expansion plans for regenerative medicine clinics
Open the full interactive Adia Nutrition, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.